Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Corient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 64.0% during the ...

Envestnet Portfolio Solutions Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company ...

JPMorgan raised the firm’s price target on Neurocrine (NBIX) to $184 from $183 and keeps an Overweight rating on the shares after surveying 24 ...

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...

Explore the exciting world of Neurocrine Biosciences (NASDAQ: NBIX) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine).